JP2014506120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506120A5 JP2014506120A5 JP2013542255A JP2013542255A JP2014506120A5 JP 2014506120 A5 JP2014506120 A5 JP 2014506120A5 JP 2013542255 A JP2013542255 A JP 2013542255A JP 2013542255 A JP2013542255 A JP 2013542255A JP 2014506120 A5 JP2014506120 A5 JP 2014506120A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- humanized antibody
- chain variable
- variable region
- occupied
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42029110P | 2010-12-06 | 2010-12-06 | |
| US61/420,291 | 2010-12-06 | ||
| US201161446990P | 2011-02-25 | 2011-02-25 | |
| US61/446,990 | 2011-02-25 | ||
| PCT/US2011/063612 WO2012078688A2 (en) | 2010-12-06 | 2011-12-06 | Humanized antibodies to liv-1 and use of same to treat cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017039373A Division JP6453924B2 (ja) | 2010-12-06 | 2017-03-02 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506120A JP2014506120A (ja) | 2014-03-13 |
| JP2014506120A5 true JP2014506120A5 (enExample) | 2015-01-08 |
| JP6105481B2 JP6105481B2 (ja) | 2017-03-29 |
Family
ID=46207694
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542255A Expired - Fee Related JP6105481B2 (ja) | 2010-12-06 | 2011-12-06 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2017039373A Active JP6453924B2 (ja) | 2010-12-06 | 2017-03-02 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2018233463A Expired - Fee Related JP6869218B2 (ja) | 2010-12-06 | 2018-12-13 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2021067924A Expired - Fee Related JP7166384B2 (ja) | 2010-12-06 | 2021-04-13 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
| JP2022170266A Pending JP2023011709A (ja) | 2010-12-06 | 2022-10-25 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
| JP2024152899A Pending JP2024178209A (ja) | 2010-12-06 | 2024-09-05 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017039373A Active JP6453924B2 (ja) | 2010-12-06 | 2017-03-02 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2018233463A Expired - Fee Related JP6869218B2 (ja) | 2010-12-06 | 2018-12-13 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2021067924A Expired - Fee Related JP7166384B2 (ja) | 2010-12-06 | 2021-04-13 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
| JP2022170266A Pending JP2023011709A (ja) | 2010-12-06 | 2022-10-25 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
| JP2024152899A Pending JP2024178209A (ja) | 2010-12-06 | 2024-09-05 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | USRE48959E1 (enExample) |
| EP (4) | EP3156420B1 (enExample) |
| JP (6) | JP6105481B2 (enExample) |
| KR (5) | KR20230057485A (enExample) |
| CN (1) | CN103533957B (enExample) |
| AU (4) | AU2011338480B8 (enExample) |
| BR (2) | BR122021020513B1 (enExample) |
| CA (2) | CA2819038C (enExample) |
| CY (3) | CY1118874T1 (enExample) |
| DK (3) | DK3156420T3 (enExample) |
| ES (3) | ES2719548T3 (enExample) |
| HR (1) | HRP20170567T1 (enExample) |
| HU (3) | HUE043355T2 (enExample) |
| IL (4) | IL299837A (enExample) |
| LT (1) | LT2648752T (enExample) |
| MX (3) | MX379481B (enExample) |
| NZ (1) | NZ611468A (enExample) |
| PL (3) | PL3461847T3 (enExample) |
| PT (3) | PT3156420T (enExample) |
| RS (1) | RS55843B1 (enExample) |
| RU (1) | RU2608646C2 (enExample) |
| SG (3) | SG10201912646UA (enExample) |
| SI (3) | SI2648752T1 (enExample) |
| WO (1) | WO2012078688A2 (enExample) |
| ZA (1) | ZA201303803B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3156420T (pt) | 2010-12-06 | 2019-05-27 | Seattle Genetics Inc | Anticorpos humanizados a liv-1 e seu uso para tratar o cancro |
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| ES2912396T3 (es) | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| SG11201504920SA (en) | 2012-12-27 | 2015-07-30 | Sanofi Sa | Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof |
| EP3027647A4 (en) * | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| EP3107557B1 (en) | 2014-02-17 | 2021-06-09 | Seagen Inc. | Hydrophilic antibody-drug conjugates |
| EP4212175A1 (en) | 2015-04-06 | 2023-07-19 | Bioverativ USA Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| MA44254A (fr) * | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques |
| EA201891968A1 (ru) * | 2016-03-15 | 2019-02-28 | Сиэтл Дженетикс, Инк. | Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства |
| EP3433278A4 (en) | 2016-03-25 | 2019-11-06 | Seattle Genetics, Inc. | METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| KR20240010534A (ko) | 2016-08-09 | 2024-01-23 | 씨젠 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
| EA201891851A1 (ru) * | 2016-09-16 | 2019-04-30 | Сиэтл Дженетикс, Инк. | Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений |
| IL326479A (en) | 2016-10-12 | 2026-04-01 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
| EA201990890A1 (ru) | 2016-10-18 | 2019-10-31 | Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида | |
| AU2018236272B2 (en) | 2017-03-15 | 2022-03-31 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| JP7527787B2 (ja) | 2017-03-24 | 2024-08-05 | シージェン インコーポレイテッド | グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体 |
| US11305224B2 (en) | 2017-04-18 | 2022-04-19 | 3M Innovative Properties Company | Air filter media with post-pleat-deposited sorbent particles |
| WO2018201087A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| BR112020004212A2 (pt) * | 2017-09-02 | 2020-09-08 | Abbvie Inc. | conjugados de fármaco de anticorpo anti-egfr (adc) e usos dos mesmos |
| BR112020004225A2 (pt) * | 2017-09-02 | 2020-09-08 | Abbvie Inc. | conjugados de fármaco de anticorpo anti-egfr (adc) e usos dos mesmos |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| CA3084495A1 (en) * | 2017-12-01 | 2019-06-06 | Seattle Genetics, Inc. | Humanized anti-liv1 antibodies for the treatment of breast cancer |
| MX2020008267A (es) | 2018-02-20 | 2020-09-21 | Seattle Genetics Inc | Compuestos de auristatina f hidrofoba y conjugados de los mismos. |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| AU2019337652A1 (en) | 2018-09-12 | 2021-03-18 | Silverback Therapeutics, Inc. | Antibody conjugates of toll-like receptor agonists |
| EP3849971A2 (en) | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| WO2020056194A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| EA202191257A1 (ru) | 2018-11-07 | 2021-12-06 | Криспр Терапьютикс Аг | Противораковая терапия на основе иммуноцитов, связывающих liv1 |
| TW202112801A (zh) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 純化遮蔽抗體之方法 |
| TW202112354A (zh) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 遮蔽抗體調配物 |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| GB201908208D0 (en) * | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
| MX2022000853A (es) | 2019-07-22 | 2022-03-17 | Seagen Inc | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer. |
| JP2022544543A (ja) | 2019-08-15 | 2022-10-19 | シルバーバック セラピューティックス インコーポレイテッド | ベンザゼピンコンジュゲートの製剤およびその使用 |
| WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| MX2022006891A (es) | 2019-12-09 | 2022-09-09 | Seagen Inc | Terapia combinada con liv1-adc y antagonista de pd-1. |
| TWI877278B (zh) | 2019-12-30 | 2025-03-21 | 美商思進公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| CN116490213A (zh) * | 2020-09-28 | 2023-07-25 | 思进股份有限公司 | 用于治疗癌症的人源化抗liv1抗体 |
| TW202229346A (zh) * | 2020-09-28 | 2022-08-01 | 美商西根公司 | 用於治療癌症之人化抗ｌｉｖ１抗體 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| AU2022270170A1 (en) * | 2021-05-07 | 2023-09-21 | Surface Oncology, LLC | Anti-il-27 antibodies and uses thereof |
| US20240352080A1 (en) | 2021-07-14 | 2024-10-24 | Seagen Inc. | Antibody Masking Domains |
| WO2023049825A1 (en) | 2021-09-24 | 2023-03-30 | Seagen Inc. | Improved antibody masking domains |
| WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
| WO2023217227A1 (zh) | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
| MA71249A (fr) | 2022-06-24 | 2025-04-30 | Bioverativ Usa Inc. | Méthodes de traitement de maladies médiées par complément |
| WO2024109944A1 (zh) * | 2022-11-25 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 抗liv-1抗体、其药物偶联物及其医药用途 |
| IL322565A (en) | 2023-02-07 | 2025-10-01 | Lanova Medicines Ltd | Antibodies targeting liv-1 and their uses |
| WO2024188339A1 (zh) * | 2023-03-15 | 2024-09-19 | 浙江博锐生物制药有限公司 | 抗liv-1抗体和抗liv-1抗体药物偶联物及其药物用途 |
| WO2025021118A1 (zh) * | 2023-07-25 | 2025-01-30 | 海南先声再明医药股份有限公司 | 配体-药物偶联物及其偶联连接子 |
| WO2025146137A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 抗liv-1抗体药物偶联物及其用途 |
| WO2025146128A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 抗liv-1的抗体及其用途 |
| WO2026142983A1 (en) * | 2024-12-23 | 2026-07-02 | Bristol-Myers Squibb Company | Liv1-tlr7/8 immunomodulatory conjugate and uses thereof |
| CN120040587B (zh) * | 2025-04-27 | 2025-08-08 | 上海宏成药业有限公司 | 抗liv-1抗体或其抗原结合片段及其用途 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1993003741A1 (en) | 1991-08-22 | 1993-03-04 | Becton, Dickinson & Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| CA2132500A1 (en) | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methods for predicting the behaviour of breast tumours |
| EP0871490B1 (en) | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| CA2269634C (en) | 1996-10-31 | 2010-08-17 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| WO1998034118A1 (en) | 1997-01-30 | 1998-08-06 | Yale University | Diagnostic methods and compositions based on the distribution of rad51 |
| WO1999023230A1 (en) | 1997-10-31 | 1999-05-14 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| JP2001523472A (ja) | 1997-11-18 | 2001-11-27 | アボット・ラボラトリーズ | 乳房の疾患の検出に有用な試薬および方法 |
| CA2316397A1 (en) | 1997-12-24 | 1999-07-08 | Corixa Corporation | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| WO2000008210A1 (en) | 1998-08-04 | 2000-02-17 | Diadexus Llc | A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| EP1121437B1 (en) | 1998-10-15 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Metastatic breast and colon cancer regulated genes |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
| US6762020B1 (en) | 1999-03-15 | 2004-07-13 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| IL150592A0 (en) | 2000-01-25 | 2003-02-12 | Genentech Inc | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| WO2001096372A2 (en) | 2000-06-13 | 2001-12-20 | University College Cardiff Consultants Ltd | Zinc transporters proteins and their use in medicinal preparations |
| US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| AU2002324451A1 (en) | 2001-06-21 | 2003-01-08 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| WO2003075855A2 (en) | 2002-03-08 | 2003-09-18 | Protein Design Labs, Inc. | Antibodies against cancer antigen tmeff2 and uses thereof |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| RS20050577A (sr) | 2003-01-27 | 2007-09-21 | Biogen Idec Ma Inc., | PREPARATI I POSTUPCI ZA TRETIRANjE KANCERA KORIŠĆENjEM IGSF9 I LIV-1 |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| KR20050010267A (ko) | 2003-07-18 | 2005-01-27 | 삼성전자주식회사 | 식각장치 |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| US7371381B2 (en) | 2003-12-12 | 2008-05-13 | Amgen Inc. | Anti-galanin antibodies and uses thereof |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AU2005290250A1 (en) | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| KR20080080482A (ko) | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 |
| KR20090010194A (ko) | 2006-04-13 | 2009-01-29 | 노바티스 백신즈 앤드 다이아그노스틱스, 인크. | 암의 치료, 진단 또는 검출 방법 |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| US20090068195A1 (en) | 2007-04-23 | 2009-03-12 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| TW200944231A (en) | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| PL2282773T3 (pl) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
| WO2010003773A1 (en) | 2008-06-16 | 2010-01-14 | Siemens Medical Solutions Diagnostics Gmbh | Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer |
| WO2010045234A1 (en) | 2008-10-14 | 2010-04-22 | University Of Louisville Research Foundation, Inc. | Methods of optimizing treatment of estrogen-receptor positive breast cancers |
| WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| US20110165566A1 (en) | 2009-07-09 | 2011-07-07 | Wittliff James L | Methods of optimizing treatment of breast cancer |
| JP5996429B2 (ja) | 2009-09-03 | 2016-09-21 | ジェネンテック， インコーポレイテッド | 関節リウマチの治療、診断及びモニターするための方法 |
| PT3156420T (pt) | 2010-12-06 | 2019-05-27 | Seattle Genetics Inc | Anticorpos humanizados a liv-1 e seu uso para tratar o cancro |
| WO2012125712A2 (en) | 2011-03-14 | 2012-09-20 | Respira Health, Llc | Lung tumor classifier for current and former smokers |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| EA201891968A1 (ru) | 2016-03-15 | 2019-02-28 | Сиэтл Дженетикс, Инк. | Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства |
| CA3084495A1 (en) | 2017-12-01 | 2019-06-06 | Seattle Genetics, Inc. | Humanized anti-liv1 antibodies for the treatment of breast cancer |
| EA202191257A1 (ru) | 2018-11-07 | 2021-12-06 | Криспр Терапьютикс Аг | Противораковая терапия на основе иммуноцитов, связывающих liv1 |
| GB201908208D0 (en) | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
-
2011
- 2011-12-06 PT PT16200557T patent/PT3156420T/pt unknown
- 2011-12-06 BR BR122021020513-2A patent/BR122021020513B1/pt active IP Right Grant
- 2011-12-06 AU AU2011338480A patent/AU2011338480B8/en not_active Ceased
- 2011-12-06 EP EP16200557.3A patent/EP3156420B1/en active Active
- 2011-12-06 SI SI201131155A patent/SI2648752T1/sl unknown
- 2011-12-06 US US15/862,389 patent/USRE48959E1/en active Active
- 2011-12-06 RS RS20170310A patent/RS55843B1/sr unknown
- 2011-12-06 ES ES16200557T patent/ES2719548T3/es active Active
- 2011-12-06 HU HUE16200557A patent/HUE043355T2/hu unknown
- 2011-12-06 MX MX2017012419A patent/MX379481B/es unknown
- 2011-12-06 WO PCT/US2011/063612 patent/WO2012078688A2/en not_active Ceased
- 2011-12-06 PL PL18204152T patent/PL3461847T3/pl unknown
- 2011-12-06 RU RU2013130609A patent/RU2608646C2/ru active
- 2011-12-06 ES ES11847198T patent/ES2620264T3/es active Active
- 2011-12-06 SG SG10201912646UA patent/SG10201912646UA/en unknown
- 2011-12-06 HU HUE11847198A patent/HUE031726T2/en unknown
- 2011-12-06 PL PL16200557T patent/PL3156420T3/pl unknown
- 2011-12-06 DK DK16200557.3T patent/DK3156420T3/en active
- 2011-12-06 CA CA2819038A patent/CA2819038C/en active Active
- 2011-12-06 ES ES18204152T patent/ES2842895T3/es active Active
- 2011-12-06 DK DK18204152.5T patent/DK3461847T3/da active
- 2011-12-06 MX MX2013006365A patent/MX351027B/es active IP Right Grant
- 2011-12-06 DK DK11847198.6T patent/DK2648752T3/en active
- 2011-12-06 KR KR1020237013204A patent/KR20230057485A/ko not_active Ceased
- 2011-12-06 KR KR1020227001675A patent/KR20220011811A/ko not_active Ceased
- 2011-12-06 BR BR112013013781A patent/BR112013013781A2/pt not_active Application Discontinuation
- 2011-12-06 PL PL11847198T patent/PL2648752T3/pl unknown
- 2011-12-06 EP EP11847198.6A patent/EP2648752B1/en active Active
- 2011-12-06 SG SG2013041926A patent/SG190938A1/en unknown
- 2011-12-06 JP JP2013542255A patent/JP6105481B2/ja not_active Expired - Fee Related
- 2011-12-06 HU HUE18204152A patent/HUE052806T2/hu unknown
- 2011-12-06 EP EP20189823.6A patent/EP3786185A1/en active Pending
- 2011-12-06 PT PT118471986T patent/PT2648752T/pt unknown
- 2011-12-06 PT PT182041525T patent/PT3461847T/pt unknown
- 2011-12-06 EP EP18204152.5A patent/EP3461847B1/en active Active
- 2011-12-06 KR KR1020197018015A patent/KR102198189B1/ko active Active
- 2011-12-06 SI SI201131936T patent/SI3461847T1/sl unknown
- 2011-12-06 SG SG10201510041QA patent/SG10201510041QA/en unknown
- 2011-12-06 US US13/990,778 patent/US9228026B2/en not_active Ceased
- 2011-12-06 KR KR1020137017660A patent/KR101993921B1/ko not_active Expired - Fee Related
- 2011-12-06 LT LTEP11847198.6T patent/LT2648752T/lt unknown
- 2011-12-06 SI SI201131705T patent/SI3156420T1/sl unknown
- 2011-12-06 KR KR1020207037466A patent/KR20200145867A/ko not_active Ceased
- 2011-12-06 CA CA3211246A patent/CA3211246A1/en active Pending
- 2011-12-06 NZ NZ611468A patent/NZ611468A/en unknown
- 2011-12-06 IL IL299837A patent/IL299837A/en unknown
- 2011-12-06 HR HRP20170567TT patent/HRP20170567T1/hr unknown
- 2011-12-06 CN CN201180058876.6A patent/CN103533957B/zh active Active
-
2013
- 2013-05-24 ZA ZA2013/03803A patent/ZA201303803B/en unknown
- 2013-06-05 IL IL226754A patent/IL226754B/en active IP Right Grant
- 2013-06-06 MX MX2020010639A patent/MX2020010639A/es unknown
-
2015
- 2015-11-20 US US14/948,183 patent/US9783608B2/en active Active
-
2017
- 2017-03-02 JP JP2017039373A patent/JP6453924B2/ja active Active
- 2017-04-27 CY CY20171100472T patent/CY1118874T1/el unknown
- 2017-06-07 AU AU2017203851A patent/AU2017203851B2/en not_active Ceased
- 2017-08-31 US US15/692,424 patent/US20180079810A1/en not_active Abandoned
-
2018
- 2018-09-20 IL IL261900A patent/IL261900A/en unknown
- 2018-12-13 JP JP2018233463A patent/JP6869218B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-11 AU AU2019202530A patent/AU2019202530B2/en not_active Ceased
- 2019-04-12 CY CY20191100414T patent/CY1121546T1/el unknown
-
2020
- 2020-02-06 US US16/784,069 patent/US20200165335A1/en not_active Abandoned
- 2020-03-25 IL IL273607A patent/IL273607B2/en unknown
- 2020-12-22 CY CY20201101211T patent/CY1123883T1/el unknown
-
2021
- 2021-04-13 JP JP2021067924A patent/JP7166384B2/ja not_active Expired - Fee Related
- 2021-06-29 AU AU2021204473A patent/AU2021204473B2/en not_active Ceased
-
2022
- 2022-10-25 JP JP2022170266A patent/JP2023011709A/ja active Pending
-
2023
- 2023-08-17 US US18/451,744 patent/US20240247059A1/en active Pending
-
2024
- 2024-09-05 JP JP2024152899A patent/JP2024178209A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102236259B1 (ko) | 항-lag-3 항체 및 그것의 사용 | |
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| RU2013130609A (ru) | Гуманизированные антитела к liv-1 и их применение для лечения рака | |
| JP2018502060A5 (enExample) | ||
| JP2014531201A5 (enExample) | ||
| JP2016536020A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| JP2017052784A5 (enExample) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2015523380A5 (enExample) | ||
| HRP20160009T1 (hr) | Protutijela anti-cd37 | |
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| JP2014039548A5 (enExample) | ||
| JP2019512464A5 (enExample) | ||
| JP2010535012A5 (enExample) | ||
| JP2013121353A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| JP2014526898A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| HRP20191678T1 (hr) | Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena |